Ormož – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:09:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ormož – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 AMBULANTA SPLOŠNE MEDICINE ALENKA SIMONIČ https://clinicaltrials.eu/site/ambulanta-splosne-medicine-alenka-simonic/ Thu, 30 Apr 2026 09:19:33 +0000 https://clinicaltrials.eu/site/ambulanta-splosne-medicine-alenka-simonic/ Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ This clinical trial is focused on studying the effects of treatments for hyperlipidemia, a condition characterized by high levels of fats, such as cholesterol, in the blood. The study will use medications containing rosuvastatin and a combination of rosuvastatin and ezetimibe. These medications are designed to help lower levels of low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol, in patients who are at high or very high risk of cardiovascular disease.

The purpose of the study is to evaluate how effective and safe these treatments are in achieving specific cholesterol level goals over a period of 12 weeks. Participants will be divided into different groups, with some receiving rosuvastatin alone and others receiving the combination of rosuvastatin and ezetimibe. The study will monitor changes in cholesterol levels at different intervals, specifically after 4, 8, and 12 weeks of treatment.

Throughout the study, participants will take the medications orally in the form of film-coated tablets. The trial aims to determine the proportion of patients who reach their LDL-C goals, which are set based on their risk levels for cardiovascular disease. The study will also assess the overall changes in cholesterol and other related blood fats to understand the effectiveness of the treatments. Participants’ adherence to the treatment regimen will be monitored to ensure accurate results.

]]>